Table 2.
Summary of plasma probe pharmacokinetic parameters after administration of probe with and without vercirnon
| Treatment | N | AUC0-∞ a | AUC0-t | Cmax | t1/2 | tmax b |
|---|---|---|---|---|---|---|
| (ng*hr/mL) | (ng*hr/mL) | (ng/mL) | (hr) | (hr) | ||
| Midazolam alone | 24 | 35.9 | 34.1 | 9.56 | 3.50 | 0.5 |
| Day 1 | (31.0, 41.7) | (29.5, 39.5) | (8.33, 10.99) | (2.97, 4.12) | (0.5–2.0) | |
| Midazolam + vercirnon | 24 | 33.0 | 31.4 | 8.60 | 3.54 | 0.5 |
| Day 11 | (29.5, 36.8) | (28.1, 35.2) | (7.52, 9.83) | (2.99, 4.18) | (0.5–2.0) | |
| Pioglitazone alone | 24 | 5248.9 | 4595.9 | 528.3 | 6.6 | 3.0 |
| Day 2 | (4685, 5881) | (4068, 5193) | (471.7, 591.7) | (5.8, 7.4) | (1.5–4.0) | |
| Pioglitazone + vercirnon | 24 | 5284.5 | 4715.8 | 569.4 | 5.3 | 3.0 |
| Day 12 | (4835, 5775) | (4230, 5257) | (522.9, 619.9) | (4.9, 5.8) | (1.5–4.0) | |
| Omeprazole alone | 24 | 634.9c | 616.4e | 256.5 | 1.08c | 4.0 |
| Day 3 | (453.0, 889.9) | (452.9, 839.1) | (179.6, 366.5) | (0.94, 1.25) | (1.5–24.0) | |
| Omeprazole + vercirnon | 24 | 626.8e | 617.4 | 275.4 | 1.18e | 4.0 |
| Day 13 | (466.9, 841.3) | (465.3, 819.3) | (208.9, 363.0) | (0.99, 1.40) | (1.0–6.0) | |
| 5-OH-omeprazole alone | 24 | 692.8d | 671.8e | 210.2 | 1.60d | 4.0 |
| Day 3 | (547.3, 877.0) | (535.0, 843.6) | (151.5, 291.5) | (1.36, 1.88) | (1.5–24.0) | |
| 5-OH-omeprazole + vercirnon | 24 | 653.0c | 660.9 | 238.7 | 1.79c | 4.0 |
| Day 13 | (576.4, 739.8) | (587.3, 743.8) | (194.9, 292.4) | (1.43, 2.25) | (1.0–6.0) | |
| Rosuvastatin alone | 24 | 28.6 | 25.3 | 2.38 | 13.15 | 4.0 |
| Day 4 | (22.9, 35.7) | (20.1, 31.8) | (1.95, 2.90) | (10.96, 15.79) | (1.0–6.0) | |
| Rosuvastatin + vercirnon | 23e | 28.4 | 25.1 | 2.50 | 11.99 | 3.0 |
| Day 14 | (23.0, 35.0) | (19.9, 31.7) | (1.97, 3.18) | (10.27, 13.99) | (1.0–6.0) |
Numbers of subjects are different because AUC values could not be calculated in a few instances
AUC 0-∞ area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time, AUC 0-t area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration, C max maximum observed concentration, t 1/2 apparent terminal phase half-life, t max time of occurrence of Cmax
aData presented as geometric mean (95 % confidence intervals) except for tmax
btmax presented as median (min-max)
c n = 21
d n = 22
e n = 23